

Concert Pharmaceuticals to Report Fourth Quarter 2021 Results on March 3, 2022

February 24, 2022

LEXINGTON, Mass.--(BUSINESS WIRE)--Feb. 24, 2022-- [Concert Pharmaceuticals, Inc.](#) (NASDAQ: CNCE) today announced that it will report its financial results for the fourth quarter of 2021, on Thursday, March 3, 2022, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m. ET to discuss its fourth quarter 2021 financial results and provide a business update. Individuals interested in participating in the call should dial (855) 354-1855 (U.S. and Canada) or (484) 365-2865 (International).

A live webcast of the conference call may be accessed in the [Investors](#) section of the Company's website at www.concertpharma.com. A replay of the webcast will be available on Concert's website for three months.

About Concert

[Concert Pharmaceuticals](#) is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its [DCE Platform](#)® (deuterated chemical entity platform). Selective incorporation of deuterium into known molecules has the potential, on a case-by-case basis, to provide better pharmacokinetic or metabolic properties, thereby enhancing their clinical safety, tolerability or efficacy. Concert's lead [product candidate](#) is in late-stage development for the treatment of alopecia areata, a serious autoimmune dermatological condition. Concert is also assessing a number of earlier-stage pipeline candidates. For more information please visit www.concertpharma.com or follow us on Twitter at [@ConcertPharma](#) or on [LinkedIn](#).

View source version on businesswire.com: <https://www.businesswire.com/news/home/20220223006144/en/>

Justine Koenigsberg
(781) 674-5284
ir@concertpharma.com

Source: Concert Pharmaceuticals, Inc.